Slow/Late Development of Secondary Sexual Characteristics (e.g. Breast) in a Female WITH a Regular Menstrual Cycle

Why Breast Development and Menstruation Can Be Dissociated

• Intact estrogen receptors in breast tissue
• Adequate local tissue response
• The timing of thelarche relative to menarche varies normally

1. Estrogen levels sufficient for endometrial cycling but below the threshold for breast growth
2. Partial end-organ insensitivity to estrogen in breast tissue specifically
3. Androgen excess opposing breast fat deposition
4. Constitutionally delayed adrenarche/thelarche that has partially corrected (menses began, breast lagging)
5. Low BMI / undernutrition - insufficient adipose substrate for breast tissue development

Differential Diagnosis

1. Constitutional / Self-Limited Delayed Puberty (Most Common)

• Accounts for ~60% of delayed puberty cases overall; represents a normal variant where 2-3% of the population falls outside the usual timing range
• The HPO axis eventually activates fully; menses may begin before breast development reaches full Tanner stage 5
• Family history of late maturation is common
• No pathology; Tanner stages simply progress slowly
• Harrison's Principles of Internal Medicine 22E

2. Androgen Excess (Hyperandrogenism)

• Elevated androgens (from polycystic ovary syndrome, congenital adrenal hyperplasia, adrenal or ovarian tumors) suppress fat deposition in breast tissue and can blunt thelarche despite normal or even slightly elevated estrogen
• PCOS classically causes irregular cycles, but milder forms may have regular menses with subtle androgen excess
• Clinical clues: hirsutism, acne, clitoromegaly

3. Low Body Weight / Eating Disorders / Excessive Exercise

• Breast tissue is largely adipose; significant underweight or low body fat delays/impairs breast development
• The HPO axis can maintain just enough estrogen for menses while breast tissue growth lags
• Functional hypogonadotropic hypogonadism accounts for ~20% of delayed puberty cases (Harrison's)

4. Partial Estrogen Receptor Insensitivity / Rare Receptor Mutations

• Very rare mutations in the estrogen receptor (ESR1) can cause selective tissue resistance - endometrium remains responsive (cycling occurs) while breast tissue growth is blunted
• Associated with tall stature, osteoporosis, elevated FSH/LH

5. Partial Gonadal Dysgenesis / Mosaicism

• Women with partial X chromosome deletions or low-level mosaicism (e.g. 45,X/46,XX) may synthesize enough estrogen for menses but insufficient for full breast development
• From Berek & Novak: "Occasionally patients with a partial deletion of the X chromosome, mosaicism, or pure gonadal dysgenesis (46,XX) may synthesize enough estrogen in..." - i.e., partial function can produce variable phenotypes
• Berek & Novak's Gynecology

6. Hyperprolactinemia (Mild/Subclinical)

• Mild prolactin elevation can impair breast development (paradoxically) and antagonize estrogen action at the breast even if cycles are maintained
• Usually causes oligomenorrhea but regular cycles are possible in mild cases

7. Hypothyroidism

• Thyroid hormone is required for normal pubertal progression and breast development
• Hypothyroidism can delay thelarche while still permitting menstruation in some cases

Tanner Staging Context

• Medical Physiology (Boron & Boulpaep)

Workup Algorithm

Key Clinical Points

• Breast development is the most estrogen-sensitive secondary sexual feature and the first to appear in puberty - it requires adequate E2, adequate local tissue, and sufficient body fat
• Regular menstruation does NOT guarantee that estrogen is high enough for full breast development - the endometrium is highly sensitive and cycles at low estrogen levels that may be insufficient for breast growth
• The most common explanation in an otherwise healthy girl is constitutional delay (slow maturers) or low body fat
• Androgen excess is an important treatable cause
• Rare but important: partial gonadal dysgenesis (karyotype-related) and estrogen receptor mutations

Treatment Options for a 19-Year-Old Female with Poor Secondary Sexual Characteristics (Breast) but Regular Menses

Step 1 - Confirm the Cause First

Treatment by Cause

A. Constitutional Delay (Slow Maturation, Normal Variant)

• At 19, this diagnosis is becoming less tenable - most constitutional delayers will have reached Tanner 4-5 by this age
• If bone age is still delayed and the girl is otherwise healthy, watchful waiting with reassurance is still an option for a short period
• However, if psychological distress is present or development has truly stalled, low-dose estrogen supplementation may be initiated to accelerate the process (see below)

B. Low Estrogen / Partial Hypogonadism - Estrogen Induction

At 19, since menses are already present, the starting dose can often be higher than in a younger girl beginning puberty induction from scratch. The goal is breast development and bone density protection.

• Katzung's Basic and Clinical Pharmacology 16th Ed

• Transdermal estradiol patches (25-100 mcg) - preferred for younger women as they bypass first-pass hepatic metabolism and have lower VTE risk than oral forms
• Oral 17β-estradiol (1-2 mg/day)
• Combined oral contraceptive pill (COCP) - a reasonable all-in-one option if contraception is also desired; the estrogen component (20-30 mcg EE) will promote breast tissue growth while the progestin provides endometrial protection

C. Low Body Weight / Eating Disorder / Excessive Exercise

1. Nutritional rehabilitation - increase caloric intake, target BMI ≥18.5; breast tissue is largely adipose and will develop naturally as body fat is restored
2. Multidisciplinary approach for eating disorders: family-based therapy is first-line for adolescents/young adults; hospitalization for severe cases
3. Exercise moderation - reduce training load if athlete-related
4. Calcium 1,200-1,500 mg/day + Vitamin D 400-800 IU/day to protect bone density
5. If hypoestrogenism persists after weight restoration, higher-dose estrogen may be needed to maintain bone density (Berek & Novak's Gynecology)
6. Note: Bisphosphonates are not recommended in young women - they deposit in bone and have unknown long-term effects, especially in future pregnancy

D. Androgen Excess (e.g. Mild PCOS / CAH)

• Combined oral contraceptive pill (COCP): first-line - suppresses LH-driven ovarian androgen production, contains estrogen that promotes breast growth, provides reliable contraception
  • Preferred: preparations containing cyproterone acetate or drospirenone (anti-androgenic progestins)
• Spironolactone 50-100 mg/day: androgen receptor blocker; adjunct to COCP if hirsutism/acne is prominent
• For CAH: low-dose glucocorticoid (hydrocortisone) to suppress ACTH-driven adrenal androgen excess

E. Hyperprolactinemia

• Discontinue any offending drug (antipsychotics, metoclopramide, domperidone)
• Dopamine agonists as primary medical therapy:
  • Cabergoline 0.25-0.5 mg twice weekly (preferred - better tolerated, more effective)
  • Bromocriptine 1.25-2.5 mg/day (alternative)
• Prolactin normalization restores normal estrogen bioavailability → breast development can resume
• Pituitary macroadenoma: neurosurgical referral if dopamine agonist therapy fails
• Berek & Novak's Gynecology

F. Hypothyroidism

• Levothyroxine (thyroxine replacement) - dose titrated to normalize TSH
• As thyroid function is restored, GH-IGF-1 axis and gonadal axis normalize, allowing pubertal completion

Bone Health - A Universal Concern at 19

• All patients should receive: Calcium 1,000-1,500 mg/day + Vitamin D 600-800 IU/day
• Estrogen therapy (when indicated) doubles as bone protection
• DEXA scan is reasonable if estrogen deficiency has been prolonged

Psychological Support

• Body image concerns are significant at 19 with underdeveloped secondary sexual characteristics
• Refer to a psychologist or counselor as part of management, particularly if there is associated anxiety, depression, or eating disorder pathology

Summary Table